Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Open-labelled, Randomised Study of Neoadjuvant Docetaxel+Oxaliplatin+S-1 (DOS) + Surgery + Adjuvant S-1 Versus Surgery + Adjuvant S-1 in Patients With Resectable Advanced Gastric Cancer

NCT01515748 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01515748
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01515748 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Open-labelled, Randomised Study of Neoadjuvant Docetaxel+Oxaliplatin+S-1 (DOS) + Surgery + Adjuvant S-1 Versus Surgery + Adjuvant S-1 in Patients With Resectable Advanced Gastric Cancer
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
December 30, 2011
Completion date
December 13, 2021
Enrollment
530 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer